Hong Sang

Array ( [id] => 17996690 [patent_doc_number] => 11497776 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => Combination therapy for a stable and long term engraftment [patent_app_type] => utility [patent_app_number] => 16/508325 [patent_app_country] => US [patent_app_date] => 2019-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 15912 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16508325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254165 [patent_doc_number] => 20190375816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => HIGH AVIDITY ANTIGEN RECOGNIZING CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 16/507803 [patent_app_country] => US [patent_app_date] => 2019-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16507803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126256 [patent_doc_number] => 20210301024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY TARGETING FLT3, PD-1, AND/OR PD-L1 [patent_app_type] => utility [patent_app_number] => 17/257553 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43845 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17257553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19904155 [patent_doc_number] => 12281151 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders [patent_app_type] => utility [patent_app_number] => 17/256788 [patent_app_country] => US [patent_app_date] => 2019-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 23069 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17256788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15023511 [patent_doc_number] => 20190322760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => TUMOR ANTIGEN SPECIFIC ANTIBODIES AND TLR3 STIMULATION TO ENHANCE THE PERFORMANCE OF CHECKPOINT INTERFERENCE THERAPY OF CANCER [patent_app_type] => utility [patent_app_number] => 16/448453 [patent_app_country] => US [patent_app_date] => 2019-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16448453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17080651 [patent_doc_number] => 20210275657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => NEOANTIGENS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/253922 [patent_app_country] => US [patent_app_date] => 2019-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 103177 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17007382 [patent_doc_number] => 20210238543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => METHODS AND MEANS FOR ATTRACTING IMMUNE EFFECTOR CELLS TO TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 16/972555 [patent_app_country] => US [patent_app_date] => 2019-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16972555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293655 [patent_doc_number] => 20190389963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => COMBINATION THERAPY BY USING ANTI-GLOBO H OR ANTI-SSEA-4 ANTIBODY WITH ANTI-NEGATIVE IMMUNE CHECK POINTS ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/429614 [patent_app_country] => US [patent_app_date] => 2019-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59489 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16429614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345315 [patent_doc_number] => 20200010549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => TREATMENT OF PD-L1-POSITIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/430106 [patent_app_country] => US [patent_app_date] => 2019-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19477 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16430106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14806333 [patent_doc_number] => 20190269776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-05 [patent_title] => AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/420511 [patent_app_country] => US [patent_app_date] => 2019-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16420511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038597 [patent_doc_number] => 20190330303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => CELL COMPOSITIONS AND METHODS FOR CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/417048 [patent_app_country] => US [patent_app_date] => 2019-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16417048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15324173 [patent_doc_number] => 20200002416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => C10RF32 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/411154 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58490 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16411154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15664067 [patent_doc_number] => 10596241 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers [patent_app_type] => utility [patent_app_number] => 16/409092 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 33109 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15290809 [patent_doc_number] => 20190388540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => HER3 INHIBITOR FOR MODULATING RADIOSENSITIVITY [patent_app_type] => utility [patent_app_number] => 16/408040 [patent_app_country] => US [patent_app_date] => 2019-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7524 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16408040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408027 [patent_doc_number] => 20200024335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => FILAMIN B BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/401071 [patent_app_country] => US [patent_app_date] => 2019-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16401071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14965553 [patent_doc_number] => 20190310255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => PROTEINS [patent_app_type] => utility [patent_app_number] => 16/385570 [patent_app_country] => US [patent_app_date] => 2019-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16385570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15117231 [patent_doc_number] => 20190345248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/384031 [patent_app_country] => US [patent_app_date] => 2019-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16384031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612197 [patent_doc_number] => 20210030850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => EXTRACELLULAR VESICLES COMPRISING TARGETING AFFINITY DOMAIN-BASED MEMBRANE PROTEINS [patent_app_type] => utility [patent_app_number] => 17/046147 [patent_app_country] => US [patent_app_date] => 2019-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038701 [patent_doc_number] => 20190330355 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME [patent_app_type] => utility [patent_app_number] => 16/380865 [patent_app_country] => US [patent_app_date] => 2019-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61553 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16380865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14594231 [patent_doc_number] => 10350292 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2019-07-16 [patent_title] => Agonist antibodies that bind human CD137 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/374412 [patent_app_country] => US [patent_app_date] => 2019-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 65 [patent_no_of_words] => 72665 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16374412 [rel_patent_id] =>[rel_patent_doc_number] =>)